Auriga - Our Business is Your Health
Capitalizing on high-revenue markets and opportunities in the pharmaceutical industry through proactive sales, integrated marketing and advanced in-house drug development capabilities
Philip S. Pesin
Chairman and CEO
Mr. Pesin, who has been a member of Auriga's board since inception, serves as the company's chairman and CEO. He brings extensive experience in establishing innovative companies in the pharmaceutical and other industries. An attorney and certified public accountant, Mr. Pesin is the founder of The Sorrento Financial Group, LLC, a financial services company specializing in private equity investment with a focus on financing innovative, high-growth companies.
Charles R. Bearchell, CPA, JD
Chief Financial Officer
Mr. Bearchell brings a wealth of Finance and Accounting expertise across multiple industries including medical, consumer products, aerospace and on-line services. Over his 30 years of experience Mr.Bearchell has held management positions in both the public and private sectors. Mr. Bearchell is a licensed CPA in the state of California. He earned a JD from Southwestern University School of Law and a BS in Business Administration/Accounting from California State University.
Andrew D. Shales
Chief Operating Officer
Mr. Shales has been a sales and marketing leader in the pharmaceutical industry for nearly 20 years with extensive experience in building commercial teams, strategic and financial planning, implementation, and opinion leader development. Most recently, His company experience includes Synthon Pharmaceuticals, First Horizon Pharmaceutical Corporation (Sciele), UCB Pharma and Solvay Pharmaceuticals.
Alan T. Roberts
Senior Vice President, Scientific Affairs
Mr. Roberts has a broad base of experience spanning more than 17 years in the technical disciplines of the pharmaceutical industry. Most recently, Mr. Roberts served as vice president, global manufacturing and development, and vice president, scientific affairs for First Horizon Pharmaceutical Corporation (Sciele), where he established the regulatory, technical, and development environments for a company transitioning from non-application, ethical pharmaceuticals to FDA-approved, application products.
Mischelle M. Hall
Vice President, Marketing
Ms. Hall is a successful pharmaceutical marketing executive experienced in a broad range of therapeutic categories. Most recently, Ms. Hall's experience includes multiple product launches, life cycle management, and marketing management positions with First Horizon Pharmaceutical Corporation (Sciele), Sigma Tau, UCB Pharma, and Synthon Pharmaceuticals.